Company Description
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States.
Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.
The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatry and neurology indications.
Bright Minds Biosciences Inc. has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin.
The company was founded in 2017 and is headquartered in New York, New York.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Ian McDonald |
Contact Details
Address: 19 Vestry Street New York, New York 10013 United States | |
| Phone | 647 865 8622 |
| Website | brightmindsbio.com |
Stock Details
| Ticker Symbol | DRUG |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | CAD |
| CIK Code | 0001827401 |
| CUSIP Number | 10919W108 |
| ISIN Number | CA10919W4056 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ian McDonald | Co-Founder, Chief Executive Officer, President and Director |
| Ryan E. S. K. Cheung B.Com., CA, CPA | Chief Financial Officer |
| Dr. Jan Torleif Pedersen M.Sc., Ph.D. | Chief Science Officer and Director |
| Dr. Mark A. Smith M.D., Ph.D. | Chief Medical Officer |
| Alex Vasilkevich | Chief Operating Officer and Vice President of Corporate Development |
| Dr. Emer Leahy M.B.A., Ph.D. | Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2025 | EFFECT | Notice of Effectiveness |
| Feb 14, 2025 | 424B3 | Prospectus |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | 6-K | Report of foreign issuer |
| Feb 10, 2025 | SCHEDULE 13G | Filing |
| Feb 7, 2025 | SCHEDULE 13G | Filing |
| Feb 5, 2025 | F-3 | Filing |